SkinHealth Systems Inc.
Close on Oct 19, 2026
- Market cap
- $1.37B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $72.10M | $-0.02 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $64.90M | $-0.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | $82.40M | $-0.06 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $70.70M | $-0.09 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $78.20M | $0.03 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $69.60M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 12, 2025 | After market close | $83.50M | $-0.08 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $78.80M | $-0.15 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDA (1)non-GAAP | Fiscal Year 2026 | $39.00M to $46.00M | Raised |
| Adjusted EBITDA (1)non-GAAP | Third Quarter 2026 | $5.00M to $7.00M | New |
| Net sales | Fiscal Year 2026 | $280.00M to $290.00M | Lowered |
| Net sales | Third Quarter 2026 | $65.00M to $70.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements SkinHealth Systems filed with the SEC
SkinHealth Systems Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
SkinHealth Systems Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
SkinHealth Systems Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
SkinHealth Systems Inc. Appoints Three New Independent Directors to Board
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
BeautyHealth Reports Full Year and Fourth Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
BeautyHealth Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The Beauty Health Company Names Pedro Malha President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BeautyHealth Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED MAY 21, 2025
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
BeautyHealth Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
BeautyHealth Reports Full Year and Fourth Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
The Beauty Health Company Strengthens Commercial Leadership Team with
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BEAUTYHEALTH NAMES SHERI LEWIS AS CHIEF SUPPLY CHAIN AND OPERATIONS OFFICER
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
BeautyHealth Appoints Stephen J. Fanning to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BeautyHealth Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
BeautyHealth Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
BeautyHealth Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
BeautyHealth Reports Full Year and Fourth Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
BeautyHealth Announces Appointment Of Marla Beck As
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BeautyHealth Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
2 business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider/ and learn more at beautyhealth.com or LinkedIn. Contacts Investors: [email protected] Press: [email protected] ###
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BeautyHealth Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
BeautyHealth Names Michael Monahan Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BeautyHealth Reports First Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Hydrafacial is upping its cool factor, one brand partnership at a time The Hydrafacial Phenomenon: Why Everyone Is Obsessed With This In-Office Treatment“ ” “ ”
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Maturing into a Multi-Brand Ecosystem, BeautyHealth
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
BeautyHealth Reports Full Year and Fourth Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Jan-19 Jul-19 Jan-20 Jun-20 Dec-20 Jun-21 Dec-21 Jun-22 Dec-22 Interest over time 2021 average
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
BeautyHealth to Acquire SkinStylus®, FDA-Cleared Microneedling Device
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
BeautyHealth Enters into $100 Million Accelerated Share Repurchase Agreement
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
BeautyHealth Reports Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
BeautyHealth Announces $200 million Share Repurchase Authorization
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
A Harbinger of Beauty Industry Resiliency,
Regulation FD disclosure · EX-99.1 to Form 8-K
Analyst & Investor Day September 15, 2022
Regulation FD disclosure · EX-99.2 to Form 8-K
BeautyHealth Reports Record Second Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K